Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Stock Information for Niagen Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Niagen Bioscience Inc.

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus(TM)
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.